RxDoctor Payments Data

Kailey Perry, PA

Physician Assistant · Gilbert, AZNPI 1104584101

Payments from drug & device makers

$3,758in general payments, 2019–2025

Across 106 payments — averaging $35.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$1K
  • Myriad Genetic Laboratories, Inc.$262
  • Pfizer$233
  • Progenics Pharmaceuticals, Inc.$224
  • Sumitomo Pharma America, Inc.$215
  • Astellas Pharma US Inc$146
  • plus $1K from 25 others

What the payments were for

  • Travel & lodging$55315%
  • Food & beverage$3,05581%
  • Education$1504%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,758 in reported general payments places this provider in the 85th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$71,893
Medicare patients
565
Services billed
1,426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron83$78,372
GemtesaVibegron43$44,827
Tamsulosin Hcl360$6,280
Silodosin45$5,229
Oxybutynin Chloride ErOxybutynin Chloride127$3,403
Dutasteride67$2,563
Trospium Chloride ErTrospium Chloride17$2,419
Bethanechol Chloride29$2,036
Solifenacin Succinate25$1,840
Testosterone Cypionate25$1,582
Trimethoprim25$1,386
Finasteride79$1,327
Alfuzosin Hcl ErAlfuzosin Hcl47$1,267
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst32$675
NitrofurantoinNitrofurantoin Macrocrystal18$541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$146$78,37283 claims
Sumitomo Pharma America, Inc.Gemtesa$215$44,82743 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Gilbert

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →